Savaria (TSX:SIS) Stock Price Nears Highs After Record Margin Beat

The market has been edging into Savaria ahead of these results, with the stock up about 4.4% over the past week to CA$30.40, and only a modest slip over the past month. The headline today is profit strength. Q2 net income reached CA$25.2m on CA$245.8m of revenue, while adjusted EBITDA margin came in at 21.1%, supported by a record 39.6% gross margin.

Short term traders are reacting to a clean beat on profitability. Long term investors will be weighing that margin profile against management’s stated long-run revenue and earnings ambitions before deciding on their next steps.

Is Savaria really trading like a mispriced compounder, or has the market already baked in these earnings and margin gains? Compare the current share price against our valuation analysis for Savaria

Q2 2026 Earnings Summary

• Revenue Q2 2026 vs. Q2 2025: CA$245.8m vs. CA$226.7m (up about 8.4%)
• Net Income Q2 2026 vs. Q2 2025: CA$25.2m vs. CA$16.3m (up about 54%)
• Basic EPS Q2 2026 vs. Q2 2025: CA$0.35 vs. CA$0.23 (up about 61.8%)
• Adjusted EBITDA Margin Q2 2026 vs. Q2 2025: 21.1% vs. about 20.5% (record 39.6% gross margin and higher consolidated profitability)

Prefer visual charts over another dense wall of earnings numbers and margin figures? See Savaria’s full financial picture, including a clear view of its valuation in our company report for Savaria.

Savaria bull case: margins and growth targets on trial

Bulls argue that Savaria is a compounding accessibility platform that can pair steady top line growth with rising margins through Savaria One, new products and M&A. Q2 gives that view some real backing. Revenue reached CA$245.8m, up 8.4% year on year with 6.6% organic growth, which lines up with management’s long term 12% annual goal when tuck ins are included. Adjusted EBITDA margin of 21.1% cleared the 20% long run target, helped by a record 39.6% gross margin and a 170 bps margin lift in Accessibility. Net earnings grew faster than revenue and operating cash flow of CA$33.3m comfortably covered CA$13.4m of capex while net debt sat at about 0.87x EBITDA. Those are the kind of milestones bulls wanted to see on efficiency, balance sheet strength and scalable growth.

Savaria bear case: growth durability and mix risks tested

The bear story centers on whether Savaria’s growth is too dependent on acquisitions and cost cuts, with real risk from weaker geographies and product mix. Q2 does not fully support that worry but it also does not erase it. Organic growth of 6.6% and Accessibility margin at 23.6% challenge the idea that efficiency gains are tapped out. However, Patient Care adjusted EBITDA margin slipped from 20.9% to 18.4% as foam and aluminum costs increased, showing how quickly input inflation can compress profits. Management has implemented a mid year price increase and is targeting margin recovery, yet that is still an execution task rather than a completed milestone. Europe remains heavily reliant on a successful Vipal integration and dealer ramp, and tuck in M&A at lower margins could still dilute group returns if integration or cross sell plans slip.

After input cost pressure in Patient Care and mixed execution risk in Europe, many investors wonder if this is just early surface noise or a sign of deeper fragility in Savaria’s story. Review our independent risk analysis for Savaria which shows 1 important warning sign

Stay Ahead With Simply Wall St

If Savaria’s latest margins and cash flow have caught your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on share price moves versus fair value and wait for your preferred entry point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and focus on concise, critical updates that matter for your thesis. For a longer term view, tap into crowd insights and different angles on Savaria through the Community and see how other investors are thinking about the same data. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market with more informed decisions.

Seeking Alternatives Beyond Savaria Now

If Savaria has you thinking about what could move next, do not wait. Fresh ideas can gain breakout momentum fast while the data still matters, so look to get in early.

• Spot high cash flow potential before it is widely discussed and scan a curated 11 high quality undervalued stocks that might still be flying under the radar for now.
• Consider structural shifts in global power demand and review a focused group of 36 power grid technology and infrastructure stocks while these opportunities are still dropping into investor screens.
• Track secular trends in factory automation and assess carefully selected 36 robotics and automation stocks while the story is still forming and before momentum catches wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com